GlassScriptPhysician profile
Natalie Diaz
NPI 1013758176
$1,588.62
in general payments reported to CMS, 2019-2025
10 companies · $864 in 2025
The $864 reported for 2025 was more than what 77% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $725 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,588.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $798.86 | 2024-2025 | Kerecis Omega3 Marigen, Kerecis Surgiclose, Kerecis Omega3 Surgiclose |
| Medtronic, INC. | $155.05 | 2025 | Venaseal |
| Smith+Nephew, INC. | $154.94 | 2025 | Grafix Pl |
| Depuy Synthes Sales INC. | $146.21 | 2025 | Motoband |
| Organogenesis INC. | $106.87 | 2025 | Puraply Wound Matrix, Apligraf |
| Davol INC. | $89.48 | 2024 | Arista Ah Flexitip |
| Solventum Corporation | $43.05 | 2024-2025 | V.A.C.Ulta, V.A.C. Veraflo, Prevena |
| Averitas Pharma INC. | $41.92 | 2024 | Qutenza |
| Nevro Corp. | $34.28 | 2024 | Senza |
| Acera Surgical, INC. | $17.96 | 2024 | Restrata Wound Matrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natalie Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.